Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Depreciation & Amortization (CF): 2020-2023

Historic Depreciation & Amortization (CF) for Cullinan Therapeutics (CGEM) over the last 4 years, with Dec 2023 value amounting to $77,000.

  • Cullinan Therapeutics' Depreciation & Amortization (CF) rose 30.51% to $77,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $310,000, marking a year-over-year increase of 233.33%. This contributed to the annual value of $306,000 for FY2024, which is 1.29% down from last year.
  • Per Cullinan Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $77,000 for Q4 2023, which was down 3.75% from $80,000 recorded in Q3 2023.
  • In the past 5 years, Cullinan Therapeutics' Depreciation & Amortization (CF) registered a high of $81,000 during Q2 2023, and its lowest value of $9,000 during Q3 2022.
  • Its 3-year average for Depreciation & Amortization (CF) is $38,000, with a median of $14,000 in 2021.
  • In the last 5 years, Cullinan Therapeutics' Depreciation & Amortization (CF) tumbled by 30.77% in 2022 and then spiked by 788.89% in 2023.
  • Cullinan Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $15,000 in 2020, then decreased by 20.00% to $12,000 in 2021, then skyrocketed by 391.67% to $59,000 in 2022, then surged by 30.51% to $77,000 in 2023.
  • Its Depreciation & Amortization (CF) stands at $77,000 for Q4 2023, versus $80,000 for Q3 2023 and $81,000 for Q2 2023.